{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+IV+infusion&page=13", "query": { "intervention": "Placebo IV infusion", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 1859, "total_pages": 186, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+IV+infusion&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+IV+infusion&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T15:34:56.948Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02908672", "title": "A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Atezolizumab Placebo", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" }, { "name": "Vemurafenib Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 514, "start_date": "2017-01-13", "completion_date": "2024-07-01", "has_results": true, "last_update_posted_date": "2025-07-20", "last_synced_at": "2026-10-15T15:34:56.948Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Tempe, Arizona • Springdale, Arkansas + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Orange", "state": "California" }, { "city": "Miami Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02908672" }, { "nct_id": "NCT02725957", "title": "A Study to Establish Safety and Maximum Tolerated Dose of IV Trehalose in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer Subjects" ], "interventions": [ { "name": "Trehalose for IV Infusion", "type": "DRUG" }, { "name": "Saline 0.9% IV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bioblast Pharma Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 24, "start_date": "2016-03", "completion_date": "2016-08", "has_results": false, "last_update_posted_date": "2016-11-22", "last_synced_at": "2026-10-15T15:34:56.948Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02725957" }, { "nct_id": "NCT03867084", "title": "Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 959, "start_date": "2019-05-28", "completion_date": "2025-09-30", "has_results": true, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-10-15T15:34:56.948Z", "location_count": 24, "location_summary": "Gilbert, Arizona • Tucson, Arizona • Duarte, California + 18 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03867084" }, { "nct_id": "NCT03782376", "title": "A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn Disease" ], "interventions": [ { "name": "Ustekinumab approximately 6 mg/kg (IV)", "type": "DRUG" }, { "name": "Placebo (SC)", "type": "DRUG" }, { "name": "Placebo (IV)", "type": "DRUG" }, { "name": "Ustekinumab 90 mg (SC) Group 1", "type": "DRUG" }, { "name": "Ustekinumab 90 mg (SC) Group 2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen-Cilag Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 215, "start_date": "2018-12-20", "completion_date": "2023-01-10", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-10-15T15:34:56.948Z", "location_count": 28, "location_summary": "La Jolla, California • Colorado Springs, Colorado • Gainesville, Florida + 22 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03782376" }, { "nct_id": "NCT05939947", "title": "A Clinical Trial of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Liver Fibrosis", "Liver Cirrhosis" ], "interventions": [ { "name": "ALE.F02", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alentis Therapeutics AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 41, "start_date": "2023-04-01", "completion_date": "2024-10-30", "has_results": false, "last_update_posted_date": "2024-12-03", "last_synced_at": "2026-10-15T15:34:56.948Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05939947" }, { "nct_id": "NCT07357675", "title": "A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Coronary Artery Disease (CAD)", "Coronary Artery Bypass Graft Surgery(CABG)" ], "interventions": [ { "name": "EA-230 90mg/kg/hour", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EBI Anti Sepsis BV", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2026-08-01", "completion_date": "2027-07-01", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-10-15T15:34:56.948Z", "location_count": 2, "location_summary": "Rochester, Minnesota • Pittsburgh, Pennsylvania", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07357675" }, { "nct_id": "NCT05929677", "title": "Impulsivity Domains and Subjective Response", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Alcohol Use Disorder" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Alcohol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jessica Weafer", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "21 Years to 25 Years" }, "enrollment_count": 250, "start_date": "2024-04-01", "completion_date": "2027-09-01", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-15T15:34:56.948Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Columbus, Ohio", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05929677" }, { "nct_id": "NCT06445075", "title": "Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Overweight and Obesity" ], "interventions": [ { "name": "Apitegromab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Tirzepatide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Scholar Rock, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 102, "start_date": "2024-05-21", "completion_date": "2025-06-17", "has_results": false, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-10-15T15:34:56.948Z", "location_count": 7, "location_summary": "Chula Vista, California • Orlando, Florida • Chicago, Illinois + 4 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Marrero", "state": "Louisiana" }, { "city": "Norman", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT06445075" }, { "nct_id": "NCT00095316", "title": "Caspofungin Study for Fungal Infections in Adults in Critical Care Settings", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Candidiasis" ], "interventions": [ { "name": "Caspofungin", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1200, "start_date": "2004-10", "completion_date": "2006-09", "has_results": false, "last_update_posted_date": "2014-12-05", "last_synced_at": "2026-10-15T15:34:56.948Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Los Angeles, California • Torrance, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00095316" }, { "nct_id": "NCT03040999", "title": "Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Head and Neck Neoplasms" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Accelerated Fractionation (AFX) Radiotherapy", "type": "RADIATION" }, { "name": "Standard Fractionation (SFX) Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 804, "start_date": "2017-04-05", "completion_date": "2024-08-21", "has_results": true, "last_update_posted_date": "2026-02-04", "last_synced_at": "2026-10-15T15:34:56.948Z", "location_count": 24, "location_summary": "Los Angeles, California • San Francisco, California • Santa Rosa, California + 21 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03040999" } ] }